ANI Pharmaceuticals, Inc. (ANIP)
NasdaqGM
Price as at 30 Sept 2026, 16:00 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
ANI Pharmaceuticals, Inc. trades at $73.12. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$46.52M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$41.99M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$14.46M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$7.95M · 0.0% of book
- Ruffer LLP, Ruffer LLP$5.74M · 0.2% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in ANIP
Trades in ANIP disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own ANIP?
9 of the institutions we track reported a position in ANIP in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ANIP data?
Fundamentals for ANIP come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:00 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ANIP, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.